Lower levels of nuclear β-catenin predict for a poorer prognosis in localized prostate cancer

International Journal of Cancer

Volumn 113, Issue 3, 2005, Pages 415-422

  Horvath, Lisa G ^a,b   Henshall, Susan M ^b   Lee, C Soon ^c,d   Kench, James G ^b,e   Golovsky, David ^b   Brenner, Phillip C ^b   O'Neill, Gordon F ^b   Kooner, Raji ^b   Stricker, Phillip D ^b   Grygiel, John J ^b   Sutherland, Robert L ^b,f  

^a SYDNEY CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

catenin; Prognostic marker; Prostate cancer; Radical prostatectomy

Indexed keywords

BETA CATENIN; NUCLEAR PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; BETA CATENIN; CADHERINS; CASE-CONTROL STUDIES; CELL NUCLEUS; CYTOSKELETAL PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 19944382766     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20599     Document Type: Article

References (48)

1. Tracey EA, Supramaniam R, Cancer in New South Wales: incidence and mortality 2000 featuring projections to 2010 for selected sites. Sydney: Cancer Council NSW, 2002.
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
3. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
4. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20:3206-12.
5. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994;125:1327-40.
6. Morin PJ. β-catenin signaling and cancer. Bioessays 1999;21:1021-30.
7. Miller JR. The Wnts. Genome Biol 2001;3:30011-15.
8. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestelli R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
9. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
10. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafargo M. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-87.
11. Truica CI, Byers S, Gelmann EP. β-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-13.
12. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002;277:1136-4.
13. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21:2629-94.
14. Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, Konishi N, Hiasa Y. E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 1999;79:1879-83.
15. Wang J, Krill D, Torbenson M, Wang Q, Bisceglia M, Stoner J, Thomas A, DeFlavia P, Dhir R, Becich MJ. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 2000;28:308-15.
16. Arenas MI, Romo E, Royuela M, Fraile B, Paniagua R. E-, N- and P-cadherin, and α-, β- and γ-catenin protein expression in normal, hyperplastic and carcinomatous human prostate cancer. Histochem J 2000;32:659-67.
17. Chesire DR, Isaacs WB. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 2002;21:8453-69.
18. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelium. Oncogene 2002;21:4099-107.
19. Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 2003;22:5602-13.
20. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002;277:30935-41.
21. Biere B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T, Taketo MM, Cardiff RD, Miyoshi K, Wagner KU, Robinson GW, Hennighausen L. Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 2003;22:3875-87.
22. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. β-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003;23:1674-87.
23. Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP. A direct β-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem 2003;278:30828-34.
24. de la Taille A, Rubin MA, Chen M-W, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D. β-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003;9:1801-7.
25. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, O'Neill G, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD. Prognostic significance of pathological features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
26. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
27. Bostwick DG, Dundore PA. Biopsy pathology of the prostate. London: Chapman and Hall Medical, 1997.
28. McNeal JE. Prostate. In: Sternberg SS, ed. Histology for pathologists. Philadelphia: Lippincott-Raven, 1997. 997-1018.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihiatsch MJ, Sauter G, Kallioniemi O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
30. Wong NACS, Pignatelli M. Beta-catenin: a linchpin in colorectal carcinogenesis? Am J Pathol 2002;160:389-401.
31. Henshall SM, Afar DEH, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-12.
32. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res 2001;61:5331-5.
33. Horvath L, Henshall S, Kench J, Saunders D, Lee C, Golovsky D, Brenner P, O'Neill G, Kooner R, Stricker P, Grygiel J, Sutherland R. Membranous secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC-3 cellular proliferation in vitro. Clin Cancer Res, in press.
34. Paul R, Ewing CM, Jarrard DF, Isaacs WB. The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 1997;79:37-43.
35. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707-13.
36. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60:3650-4.
37. Michaelson JS, Leder P. β-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland. Oncogene 2001;20:5093-9.
38. Miyazawa K, Iwaya K, Kuroda M, Harada M, Serizawa H, Koyanagi Y, Sato Y, Mizokami Y, Matsuoka T, Mukai K. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. Virch Arch 2000;437:508-13.
39. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K. A novel frizzled gene identified in human esophageal carcinoma mediates APC/β-catenin signals. Proc Natl Acad Sci USA 1998;95:10164-9.
40. Voeller HJ, Truica CI, Gelmann EP. β-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-3.
41. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih IM, Buhler K, Pienta K, Rubin MA, Vessella R, Papadopoulos N. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002;34:9-16.
42. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
43. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. β-catenin; a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA 2000;97:4262-6.
44. Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME. Liganded androgen receptor interaction with β-catenin. J Biol Chem 2002;277:20702-10.
45. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and co-operates with Ras in transformation. EMBO J 2001;20:4912-22.
46. Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S, Noda T, Arai Y, Miyazono K, Kato M. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor β-induced repression of c-myc. Cancer Res 2003;63:801-6.
47. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
48. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Leal JF, Zhuinsky J, Geiger B, Oren M. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999;18:3054-63.